Docket No: AM101214
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: Diane H. Boschelli et al.
Application No.:   10/780,973   Group Art No.:   1614
Filed: February 18, 2004   Examiner:
For: 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Alkoxy-3-
                            Quinolinecarbonitriles for the Treatment of Ischemic Injury
Confirmation No.:   1683
Customer Number: 25291

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

1.   <u>Preliminary Statements</u>
       In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents,
       publications, or other information of which they are aware, which they believe may be
       material to the examination of this application and in respect of which there may be a
       duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure
       Statement is not to be construed as a representation that: (i) a search has been
       made; (ii) the information is material to the examination of this application; (iii)
       additional information material to the examination of this application does not exist; (iv)
       the information, protocols, results and the like reported by third parties are accurate or
       enabling; or (v) the information constitutes prior art to the subject invention.

2. Identification of Time of Filing
   This Information Disclosure Statement
   a. ☐ is filed within three months of the filing date of the application.
   b. ☒ is filed before the mailing date of a first Office Action on the merits.
   c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
   d. ☒ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
   e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☒ Certification under 37 CFR 1.97(e) and 1.704(d)
   The undersigned attorney certifies

   a. ☒ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
   b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
   c. ☒ certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☒ Newly Cited Information
   A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.

☐ Previously Cited Information
   No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.
   Prior application is Application Number   , filed on   of   for

☐ Concise Explanation
Documents cited above which are not in the English Language

a.　☐　have been explained in the specification.

b.　☐　have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

☐ Fees
　☐　Fee for filing under 37 CFR 1.97(c) or (d)　　Fee: $180.00

Method of Payment of Fees:
Charge Deposit Account No. 01-1425 in the amount of
A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:
Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.

Rebecca R. Barrett
August 16, 2004
Attorney for Applicants
Reg. No. 35,152

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (484) 865-8607

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	2002/0026052	A1	Diane H. Boschelli et al.	02-28-2002	

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
.	2.	Dan BERGER et al., Bioorganic & Medicinal Chemistry Letters, 2002, 2989-2992, 12	☐
	3.	Diane H. BOSCHELLI et al., Bioorganic & Medicinal Chemistry Letters, 2003, 3797-3800, 13	☐

Examiner Signature		Date Considered	